Market Overview

UPDATE: Goldman Sachs Upgrades Zimmer Holdings to Neutral on Improving Orthopedic Volumes

Related ZMH
Zimmer Provides Update On The European Commission Review Process Relating To The Pending Merger With Biomet, Inc.
Zimmer Announces FDA Clearance Of The Stand-alone Optio-C Anterior Cervical System For Use With Structural Allograft/Autograft

Goldman Sachs raised its rating on Zimmer Holdings (NYSE: ZMH) from Sell to Neutral and increased its price target from $58 to $70.

Goldman Sachs noted, "Our investment thesis is based on the following factors: (1) improving outlook on US orthopaedic surgical volumes; (2) decelerating rates of pricing pressure; (3) capital allocation optionality with the potential for larger free cash flow returns to shareholders; and (4) shares appear fairly valued at current levels. Since being added to the Americas Sell List on August 9, 2011, ZMH shares are up 20.5% vs. the S&P 500 up 21.0%. On a trailing 12-month basis, ZMH is +33.0% vs. the S&P 500 +13.0%."

Zimmer Holdings closed at $65.50 on Monday.

Latest Ratings for ZMH

DateFirmActionFromTo
Dec 2014Leerink SwannMaintainsOutperform
Dec 2014BarclaysMaintainsOverweight
Oct 2014JP MorganMaintainsNeutral

View More Analyst Ratings for ZMH
View the Latest Analyst Ratings

Posted-In: Goldman SachsAnalyst Color Upgrades Intraday Update Analyst Ratings

 

Related Articles (ZMH)

Around the Web, We're Loving...

Get Benzinga's Newsletters